Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (3)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
3 additional source qualifications - review before use
The generic BONIVA page retrieved injection content. Only the explicitly identified injection page was imported as new renal guidance; no oral regimen was inferred from the generic-title page.
Before applying: Read the route on the source card, not only the directory name. Do not transfer the injection monitoring or administration schedule to tablets.
The original injection-specific source is preserved. The new official oral-tablet source is a separate formulation record, not a correction made inside the injection card.
Before applying: Use the formulation selector to inspect the matching product. The generic-title RX page remains on hold.
Measure serum creatinine before every injection. Verify the current injection label before use of this dated FDA source.
Before applying: Verify the current prescribing information for this presentation.
Also check: BONIVA index name does not establish an oral formulation; BONIVA: keep injection and oral records separate; Boniva injection - product and source limitations
Official source
Boniva injection - labeled renal guidance
Renal action and limits
Ibandronate (Boniva Injection), adult IV injection for postmenopausal osteoporosis Creatinine clearance (CrCl), mL/min; use the product-specific calculation
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Action or finding
Do not administer IV Boniva when CrCl is below 30 mL/min. At or above 30, renal impairment does not require a dose change.
Limits and monitoring
Measure serum creatinine before every injection. Verify the current injection label before use of this dated FDA source.
Before use
Verify the current prescribing information for this presentation.
Ibandronate (Boniva Injection), adult IV injection for postmenopausal osteoporosis
Renal measure
Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source revision
Prescribing information revised 04/2015
Retrieved
2026-11-07 (not the revision date)
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Renal guidance: 2.6 and 5.3
Do not administer IV Boniva when CrCl is below 30 mL/min. At or above 30, renal impairment does not require a dose change. Measure serum creatinine before every injection. Verify the current injection label before use of this dated FDA source.
Source revision: Prescribing information revised 04/2015 | Retrieved: 2026-11-07. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
product or method difference
BONIVA index name does not establish an oral formulation
The generic BONIVA page retrieved injection content. Only the explicitly identified injection page was imported as new renal guidance; no oral regimen was inferred from the generic-title page.
How to use this: Read the route on the source card, not only the directory name. Do not transfer the injection monitoring or administration schedule to tablets.
The original injection-specific source is preserved. The new official oral-tablet source is a separate formulation record, not a correction made inside the injection card.
How to use this: Use the formulation selector to inspect the matching product. The generic-title RX page remains on hold.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source
Boniva injection - labeled renal guidance
Ibandronate (Boniva Injection), adult IV injection for postmenopausal osteoporosis
Method: Creatinine clearance (CrCl), mL/min; use the product-specific calculation
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Do not administer IV Boniva when CrCl is below 30 mL/min. At or above 30, renal impairment does not require a dose change. Measure serum creatinine before every injection. Verify the current injection label before use of this dated FDA source.
RDM73-boniva-official-1 · Source locator: Renal guidance: 2.6 and 5.3
GlobalRPh-hosted RX List · BONIVA intravenous injection; adult postmenopausal osteoporosis. Not the oral tablet.
Renal method: CrCl in mL/min; serum creatinine before each injection. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Do not administer the injection when CrCl is below 30 mL/min. Obtain serum creatinine before each injection and withhold treatment when renal function deteriorates. The source reports acute renal failure with intravenous bisphosphonates and recommends additional monitoring for patients at increased risk or receiving nephrotoxic medicines. This extract covers renal eligibility and monitoring, not the complete injection prescription.
RDM43-rxlist-ibandronate-boniva-injection-18372923e2-C1 · Source locator: Selected Dosage / Renal Impairment / Warnings sections; see source-specific qualifications in this summary.
GlobalRPh RX List / product-label mirror · Ibandronate (Boniva Injection), adult IV injection for postmenopausal osteoporosis
Renal method: Use the renal measure explicitly present in the RX passage. Source date: Mirror revision not established in the reviewed passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Additional summaries stored on this page: 1 official-label, 2 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.
